Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 21, 2020 - Issue 1
Submit an article Journal homepage
1,412
Views
1
CrossRef citations to date
0
Altmetric
Editorial

Selecting dopamine depleters for hyperkinetic movement disorders: how do we choose?

Laszlo Szpisjaka Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, HungaryView further author information
,
Andras Salamona Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, HungaryView further author information
,
Denes Zadoria Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, HungaryView further author information
,
Peter Klivenyia Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, HungaryView further author information
&
Laszlo Vecseia Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Szeged, Hungary;b MTA-SZTE Neuroscience Research Group, Szeged, Hungary;c Department of Neurology, Interdisciplinary Excellence Centre, University of Szeged, Szeged, HungaryCorrespondence[email protected]
View further author information
Pages 1-4 | Received 29 Aug 2019, Accepted 24 Oct 2019, Published online: 30 Oct 2019

References

  • Jankovic J. Dopamine depleters in the treatment of hyperkinetic movement disorders. Expert Opin Pharmacother. 2016;17:2461–2470.
  • Citrome L. Tardive dyskinesia: placing vesicular monoamine transporter type 2 (VMAT2) inhibitors into clinical perspective. Expert Rev Neurother. 2018;18:323–332.
  • Kaur N, Kumar P, Jamwal S, et al. Tetrabenazine: spotlight on drug review. Ann Neurosci. 2016;23:176–185.
  • Kenney C, Hunter C, Mejia NI, et al. Tetrabenazine in the treatment of Tourette syndrome. J Pediatr Neurol. 2007;05:009–013.
  • Huntington Study Group. Tetrabenazine as antichorea therapy in huntington disease: a randomized controlled trial. Neurology. 2006;66:366–372.
  • Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord. 2007;22:193–197.
  • Scorr LM, Factor SA. VMAT2 inhibitors for the treatment of tardive dyskinesia. J Neurol Sci. 2018;389:43–47.
  • Huntington Study Group. Effect of deutetrabenazine on chorea among patients with huntington disease: a randomized controlled trial. JAMA. 2016;316:40–50.
  • Bashir H, Jankovic J. Deutetrabenazine for the treatment of Huntington’s chorea. Expert Rev Neurother. 2018;18:625–631.
  • Fernandez HH, Factor SA, Hauser RA, et al. Randomized controlled trial of deutetrabenazine for tardive dyskinesia: the ARM-TD study. Neurology. 2017;88:2003–2010.
  • Anderson KE, Stamler D, Davis MD, et al. Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Psychiatry. 2017;4:595–604.
  • Fernandez HH, Stamler D, Davis MD, et al. Long-term safety and efficacy of deutetrabenazine for the treatment of tardive dyskinesia. J Neurol Neurosurg Psychiatry. 2019. published online 2019 Jul 10. DOI:10.1136/jnnp-2018-319918.
  • Jankovic J, Jimenez-Shahed J, Budman C, et al. Deutetrabenazine in tics associated with Tourette syndrome. Tremor Other Hyperkinet Mov (NY). 2016;6:422.
  • O’Brien CF, Jimenez R, Hauser RA, et al. NBI-98854, a selective monoamine transport inhibitor for the treatment of tardive dyskinesia: a randomized, double-blind, placebo-controlled study. Mov Disord. 2015;30:1681–1687.
  • Hauser RA, Factor SA, Marder SR, et al. KINECT3: a phase 3 randomized, double-blind, placebo-controlled trial of valbenazine for tardive dyskinesia. Am J Psychiatry. 2017;174:476–484.
  • Factor SA, Remington G, Comella CL, et al. The effects of valbenazine in participants with tardive dyskinesia: results of the 1-year KINECT 3 extension study. J Clin Psychiatry. 2017;78:1344–1350.
  • Correll CU, Cutler AJ, Kane JM, et al. Characterizing treatment effects of valbenazine for tardive dyskinesia: additional results from the KINECT 3 study. J Clin Psychiatry. 2018;80:18m12278. DOI:10.4088/JCP.18m12278.
  • Claassen DO, Carroll B, De Boer LM, et al. Indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease. J Clin Mov Disord. 2017;4:3.
  • Rodrigues FB, Duarte GS, Costa J, et al. Meta-research metrics matter: letter regarding article “indirect tolerability comparison of deutetrabenazine and tetrabenazine for Huntington disease”. J Clin Mov Disord. 2017;4:19.
  • Niemann N, Jankovic J. Real-world experience with VMAT2 inhibitors. Clin Neuropharmacol. 2019;42:37–41.
  • Niemann N, Jankovic J. Treatment of tardive dyskinesia: a general overview with focus on the vesicular monoamine transporter 2 inhibitors. Drugs. 2018;78:525–541.
  • Aggarwal S, Serbin M, Yonan C. Indirect treatment comparison of valbenazine and deutetrabenazine efficacy and safety in tardive dyskinesia. J Comp Eff Res. 2019;8:1077–1088.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.